140 related articles for article (PubMed ID: 34392287)
21. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.
Bach-Gansmo T; Korsan K; Bogsrud TV
Tomography; 2022 Jun; 8(3):1477-1484. PubMed ID: 35736868
[TBL] [Abstract][Full Text] [Related]
22. A bicentric retrospective analysis of clinical utility of
Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
[TBL] [Abstract][Full Text] [Related]
23. Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer.
Chaussé G; Abikhzer G; Probst S
Clin Nucl Med; 2018 Apr; 43(4):250-251. PubMed ID: 29465489
[TBL] [Abstract][Full Text] [Related]
24. The "Ultimate Triple PET": 68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer.
McClenathan M; Peacock JG
Clin Nucl Med; 2022 Feb; 47(2):e161-e164. PubMed ID: 34392283
[TBL] [Abstract][Full Text] [Related]
25. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract][Full Text] [Related]
26. Lung Metastasis From Prostate Cancer Revealed by 18F-FDG PET/CT Without Osseous Metastasis on Bone Scan.
Su HY; Chen ML; Hsieh PJ; Hsieh TS; Chao IM
Clin Nucl Med; 2016 May; 41(5):392-3. PubMed ID: 26859201
[TBL] [Abstract][Full Text] [Related]
27.
Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
[TBL] [Abstract][Full Text] [Related]
28.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
30. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
[TBL] [Abstract][Full Text] [Related]
31. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
32. The Great Mimicker-Tuberculosis Involving Prostate and Vertebrae Posing as Metastatic Prostate Carcinoma on FDG PET/CT.
Joshi PV; Shewalkar B; George T; Sahasrabudhe S; Joshi S; Kulkarni M
Clin Nucl Med; 2020 Mar; 45(3):206-208. PubMed ID: 31652162
[TBL] [Abstract][Full Text] [Related]
33. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract][Full Text] [Related]
34. Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT.
Baiomy A; Martiniova L; Efstathiou E; Schuster DM; Ravizzini G
Clin Nucl Med; 2021 Apr; 46(4):e240-e241. PubMed ID: 33208612
[TBL] [Abstract][Full Text] [Related]
35. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
36. Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis.
Qi J; Nguyen NC
Clin Nucl Med; 2022 Dec; 47(12):1061-1062. PubMed ID: 36026595
[TBL] [Abstract][Full Text] [Related]
37. Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence.
Nguyen NC; Muthukrishnan A; Mountz JM
Clin Nucl Med; 2020 Jan; 45(1):e63-e64. PubMed ID: 31652158
[TBL] [Abstract][Full Text] [Related]
38. Comparison of
Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG and 18F-Fluciclovine Uptake in Poorly Differentiated Lung Adenocarcinoma in the Setting of Biochemically Recurrent Prostatic Adenocarcinoma.
Trak J; Hasanovic A; Gavane S
Clin Nucl Med; 2022 Dec; 47(12):1077-1078. PubMed ID: 36342794
[TBL] [Abstract][Full Text] [Related]
40. Solitary Penile Metastasis of Prostate Cancer on 18F-Fluciclovine PET/CT Imaging in a Patient With PSA of 1 ng/mL.
Salavati A; Schik AN; Koksel Y; Gencturk M; Froelich JW
Clin Nucl Med; 2020 May; 45(5):389-391. PubMed ID: 32149799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
